Amarin's Vascepa patent defense ends in a loss at the Supreme Court

For a drug company with one commercial product, losing a patent challenge right on the heels of a major new FDA approval is a serious setback. That’s why Amarin took its Vascepa patent defense all the way to the Supreme Court, but it has fallen short.